Astellas geritinib fumarate tablets reach the primary endpoint of overall survival

Astellas Pharmaceuticals Group (TSE: 4503, President and CEO: Dr.

The COMMODORE trial is a multicenter open randomized controlled study conducted in China and other countries to compare the efficacy of geritinib treatment and salvage chemotherapy in adult patients with relapsed or refractory FLT3 mutant AML.

Earlier this year, the China National Medical Products Administration (NMPA) conditionally approved geritinib for the treatment of FMS-like tyrosine kinase 3 (FLT3) mutations detected by fully validated detection methods Adult patients with relapsed or refractory acute myeloid leukemia (AML).

Astellas plans to submit COMMODORE's test results to the China National Medical Products Administration for regular approval for marketing.

Acute myeloid leukemia is a tumor that affects the blood and bone marrow, and its incidence increases with age.

In an earlier trial, 319 patients with relapsed or refractory acute myeloid leukemia (with FLT3 mutation) who received at least one dose of 120 mg/day of geritinib were evaluated for the safety of geritinib.

Note: The original text has been deleted